74C.F CROSSJECT SA EO -10
- Market cap
- EUR 81.1M
- P/E
- -
- P/B
- 25.43x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 74C.F undervalued?
Graham numberThe Graham number of CROSSJECT SA EO -10 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CROSSJECT SA EO -10 fundamental analysis
No fundamental analysis for CROSSJECT SA EO -10 yet.
CROSSJECT SA EO -10 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CROSSJECT SA EO -10
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. It offers Midazolam for epileptic seizure; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In additio…
Full company profileCROSSJECT SA EO -10 financial statements
CROSSJECT SA EO -10 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 912K | 954K | 145K | 0.00 | 0.00 |
| Gross Profit | -390K | -1.21M | -6.14M | -9.25M | -9.71M |
| Operating Income | -11.8M | -13.3M | -11.6M | -13.0M | -11.6M |
| EBITDA | - | -7.58M | -6.27M | -7.76M | -6.05M |
| Net Income | -10.8M | -11.2M | -8.64M | -12.8M | -10.4M |
| EPS | -0.40 | -0.30 | -0.23 | -0.28 | -0.20 |
| Balance Sheet | |||||
| Total Assets | 31.5M | 32.9M | 28.6M | 31.6M | 30.4M |
| Total Liabilities | 37.0M | 30.2M | 33.9M | 34.2M | 35.3M |
| Shareholders' Equity | -5.48M | 2.69M | -5.27M | -2.67M | -4.87M |
| Cash & Short-term Investments | 9.98M | 7.77M | 2.30M | 7.04M | 5.08M |
| Cash Flow | |||||
| Operating Cash Flow | -6.08M | -5.08M | -6.20M | -7.96M | -6.35M |
| Capital Expenditure | 6.73M | 6.78M | 6.40M | 3.53M | 4.50M |
| Free Cash Flow | -12.8M | -11.9M | -12.6M | -11.5M | -10.8M |
| Ratios | |||||
| ROE | - | -415.4% | - | - | - |
| ROA | -34.3% | -34.0% | -30.2% | -40.5% | -34.1% |
| Net Profit Margin | -1,184.9% | -1,169.5% | -5,958.6% | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
CROSSJECT SA EO -10 dividends
CROSSJECT SA EO -10 has not paid dividends in the last 5 fiscal years.
Who owns CROSSJECT SA EO -10
- Insiders 19.63%
- Institutions 0.40%
- Public & others 79.97%
- Shares outstanding 60.6M
- Free float 51.2M
CROSSJECT SA EO -10 company profile
- Company name
- CROSSJECT SA EO -10
- Ticker
- 74C.F
- ISIN
- FR0011716265
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 99
- Fiscal year end
- December
- Address
- 6 Rue Pauline Kergomard, Dijon, France, 21000
- Phone
- 33 3 80 54 98 50
- Website
- crossject.com
About CROSSJECT SA EO -10
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. It offers Midazolam for epileptic seizure; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In addition, the company is developing ZEPIZURE, an emergency treatment for managing epileptic seizures. The company was incorporated in 2001 and is based in Dijon, France.
CROSSJECT SA EO -10 management
6- Mr. Patrick AlexandreCo-Founder, CEO & Chairman of the Executive Board
- Mr. Lionel SeltzCO & Member of Executive Board
- Dr. Isabelle LiebschützChief Quality & Regulatory Officer and Member of Executive Board
- Dr. Olivier Lacombe PH.D.Pharmaceutical Development Director & Member of Executive Board
- Mr. Didier MorinIndustrial Director & Member of Executive Board
- Mr. Tony TiptonChief Operating Officer of U.S